What is the product positioning strategy for two novel early stage IO candidates for global pharma company?
Which indications should the IO candidates be prioritized for?
How does the product positioning affect the overall IO portfolio for the company?
Go/no-go decision on mono / combotherapy
What We Did
Workshop with client for indication prioritization
TPP generation for each candidate across indications
Determined the impact of the candidate on the overall portfolio
Prioritized the indication selections
Our Results And Insight
Estimated revenue potential
See other case studies
Commercial Strategy case studies >
Portfolio Management case studies >
Oncology case studies >
Auto-immune case studies >
Service Areas Details
Commercial Strategy, Portfolio Management (Disease Area Strategy)
Therapeutic Areas Details
Oncology (Solid Tumor), Auto-immune